Hematological Cancer Research Investment and Education Act

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, May 12, 2023
CLL, Waldenström macroglobulinemia, Mayo Clinic, Arm, Chronic lymphocytic leukemia, Follicular lymphoma, Fred Hutchinson Cancer Research Center, ICML, Clinical trial, Lymphoma, Security agreement, Research, Runway, Translation, WM, Waldenström, CAR, Hematological Cancer Research Investment and Education Act, International Conference on Afghanistan, London (2010), Patient, Clinical professor, FDA, Loan, Mustang, Conference, DSM-IV codes, Safety, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.
  • The final dose level escalation is anticipated in the Phase 1 indolent lymphoma arm in the third quarter of this year.
  • Research and development expenses were $14.0 million for the first quarter of 2023, compared to $16.3 million for the first quarter of 2022.
  • General and administrative expenses were $2.3 million for the first quarter of 2023, compared to $3.3 million for the first quarter of 2022.

Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy

Retrieved on: 
Thursday, May 11, 2023
University, European Hematology Association, Chronic lymphocytic leukemia, Follicular lymphoma, Fred Hutchinson Cancer Research Center, DSM-IV codes, University of Washington, Lymphoma, Associate, Translation, CAR, Hematological Cancer Research Investment and Education Act, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Mustang, Conference, Safety, Pharmaceutical industry

WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”), will be presented at the European Hematology Association (“EHA2023”) Hybrid Congress taking place June 8-11, 2023, in Frankfurt, Germany and at the International Conference on Malignant Lymphoma (“ICML”) taking place June 13-17, 2023, in Lugano, Switzerland.

Key Points: 
  • Both presentations will be given by Mazyar Shadman, M.D., M.P.H., Associate Professor and physician at Fred Hutchinson Cancer Center (“Fred Hutch”) and University of Washington.
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutch.
  • “As we continue to progress our CD20-targeted CAR T cell therapy program, we look forward to the upcoming presentations highlighting data from the Phase 1/2 study of MB-106 taking place at Fred Hutch.
  • “Looking ahead, Mustang plans to provide a data update in the near future from our Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106 in a multicenter setting.”
    Details of the presentations are as follows:

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, May 11, 2023
Topotecan, GLP, Carcinoma, Abstract, Rituximab, LSD1, AACR, Cancer prevention, Follicular lymphoma, DLBCL, European Hematology Association, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Biotechnology, Clinical trial, Lenalidomide, NHL, CD20, American Association for Cancer Research, Cyclophosphamide, Salinicola salarius, SCLC, Bortezomib, Congress, Investigational New Drug, Hematological Cancer Research Investment and Education Act, Patient, Toxicology, Neoplasm, Ewing sarcoma, Research institute, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, News, Food, Cancer Prevention and Research Institute of Texas, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Video game

HOUSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $9.3 million as of March 31, 2023, compared with $12.1 million as of December 31, 2022.
  • The decline reflects lower spending on seclidemstat in the 2023 quarter and one-time expenses of $2.0 million related to the purchase of the targeted protein degrader program in the 2022 quarter.
  • “In addition, Salarius continued to execute on plan during the first quarter of 2023 and recent weeks as we advanced the development of SP-3164, our targeted protein degrader.
  • Salarius will be participating in the 2023 BIO International Convention in Boston June 5-8, and the European Hematology Association 2023 Congress in Frankfurt, Germany June 8-11.

IMV Receives NASDAQ Delisting Notice

Retrieved on: 
Monday, May 8, 2023
Oncology, Professional Services, Health, Other Health, Finance, Pharmaceutical, Biotechnology, IMV, Failure, Electric Bond and Share Company v. Securities and Exchange Commission, Nova Scotia Supreme Court, Hematological Cancer Research Investment and Education Act, Bankruptcy Code, TSX, Letter, Cryptocurrency

IMV Inc. (the “Company” or “IMV”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the “Initial Order”) granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the “CCAA”).

Key Points: 
  • IMV Inc. (the “Company” or “IMV”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the “Initial Order”) granting the Company and its subsidiaries protection under the Companies’ Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the “CCAA”).
  • The Company also announced on such date that it will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.
  • Nasdaq informed the Company that trading in the Company's common shares would be suspended at the opening of business on May 11, 2023, and a Form 25-NSE will be filed with the United States Securities and Exchange Commission, which will remove the Company’s common shares from listing on the Nasdaq.
  • IMV previously announced on March 31, 2023, its receipt of a letter from the Nasdaq Listing Qualifications Department regarding its failure to meet the minimum bid price of US$1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2).

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Call, Total, AACR, TCL, PRS, ALC, RCC, Neoplasm, KCRC, ITK, Clinical trial, Extranodal NK/T-cell lymphoma, nasal type, American Association for Cancer Research, Head, T-cell lymphoma, NSCLC, Lung cancer, Immunotherapy, Bone marrow, Hematological Cancer Research Investment and Education Act, Patient, Ipilimumab, BID, Blood, Immune system, Kidney cancer, CR, Growth, Research, FDA, B16, Pembrolizumab, PR, Safety, Nivolumab, Pharmaceutical industry, Cryptocurrency, Corvus, Conference

BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March 31, 2023.
  • The clinical trial is expected to enroll up to 60 patients and initial data is anticipated before the end of 2023.
  • As of March 31, 2023, Corvus had cash, cash equivalents and marketable securities totaling $34.5 million.
  • The decrease of $0.5 million was primarily due to lower clinical trial and manufacturing costs associated with the development of mupadolimab.

SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study

Retrieved on: 
Thursday, May 4, 2023
Pharmacodynamics, Lymphoma, MYC, University, PD, BMB, Leukemia Research, Therapeutic index, Survival, Bone marrow, Associate, Acute myeloid leukemia, MRD, AML, Azacitidine, Hematological Cancer Research Investment and Education Act, Doctor of Science, SLS, MD, Patient, Cure, MCL1, CR, Toxic leukoencephalopathy, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Leukemia, CDK9, BIW, Food, Pharmaceutical industry, Vaccine, Hematology

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced positive topline data for the cohort of patients with acute myeloid leukemia (AML) from its Phase 1 dose-escalation trial in relapsed/refractory (r/r) myeloid malignancies for GFH009, its CDK9 inhibitor. Dose escalation continues in the lymphoma cohort with the last dose level of 75 mg weekly. Clinical activity observed in the lymphoma group will be announced after completion of the last dose level and is expected by the end of the second quarter or early third quarter of 2023.

Key Points: 
  • Dose escalation continues in the lymphoma cohort with the last dose level of 75 mg weekly.
  • In the cohort of patients with AML, GFH009 treatment showed evidence of anti-tumor activity increasing with higher doses and no significant safety issues, including at the highest dose levels.
  • The recommended Phase 2 dose (RP2D) for AML has been established and submitted to the U.S. Food and Drug Administration (FDA).
  • SELLAS plans to commence a Phase 2a trial with GFH009 in combination with venetoclax and azacitidine (aza/ven) in patients with AML during the second quarter of 2023 with topline data expected by the end of the year.

IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives

Retrieved on: 
Monday, May 1, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Exercise, IMV, Toronto Stock Exchange, Clinical trial, Cancer, CCAA, DPX, Sale, Nova Scotia Supreme Court, Hematological Cancer Research Investment and Education Act, Patient, Laboratory, Bankruptcy Code, Court, TSX, Monitor, News, Pharmaceutical industry

The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.

Key Points: 
  • The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.
  • The Court has appointed FTI Consulting Canada Inc. to serve as the Monitor in the CCAA proceedings and to assist the Company with its restructuring efforts and report to the Court during the restructuring.
  • At this time, the Company expects that it will have sufficient funds to complete its CCAA proceedings and potential restructuring.
  • Further news releases will be provided on an ongoing basis throughout the CCAA proceedings as required by law or otherwise as may be determined necessary by the Company or the Court.

Inspirna Appoints Dr. Usman “Oz” Azam, M.D., as New Chief Executive Officer

Retrieved on: 
Monday, May 1, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Empyrean, GSK, Drug development, Central nervous system, Genetic engineering, Therapy, Gene, University, National Science Advisory Board for Biosecurity, Cancer, Gynaecology, University of Liverpool School of Medicine, Hematological Cancer Research Investment and Education Act, Novartis, Cell, Obstetrics, United Kingdom, Johnson & Johnson, FDA, Pharmaceutical industry, Pfizer

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today the appointment of Dr. Usman “Oz” Azam, M.D., as its new Chief Executive Officer.

Key Points: 
  • Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today the appointment of Dr. Usman “Oz” Azam, M.D., as its new Chief Executive Officer.
  • Masoud Tavazoie, M.D., Ph.D., co-founder of Inspirna, recently stepped down as Chief Executive Officer and Director and will assume a new role as Advisor to provide ongoing support to the Company.
  • “2023 is a compelling year for Inspirna as the company continues to advance its clinical and preclinical pipeline.
  • Dr. Azam has also held roles as Chief Executive Officer of Novaccel Therapeutics, Chief Medical Officer of Aspreva Pharmaceuticals, and Chief Medical Officer of Ethicon Johnson & Johnson.

Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids

Retrieved on: 
Wednesday, April 26, 2023
Fas, TNF, CD95, Fas receptor, Survival, Research, Hematological Cancer Research Investment and Education Act, CAR, Apoptosis, Chimera, Neoplasm, Fas ligand, Vaccine

One such inhibitory factor is Fas ligand (FasL), which binds to the Fas receptor (CD95) on the surface of an activated T cell and triggers the CAR T cell to die by apoptosis.

Key Points: 
  • One such inhibitory factor is Fas ligand (FasL), which binds to the Fas receptor (CD95) on the surface of an activated T cell and triggers the CAR T cell to die by apoptosis.
  • The research group at Autolus tested several Fas chimeras which consist of the extracellular domain of Fas fused to the intracellular domain from different TNF receptor superfamily members.
  • Expression of these chimeras in a CAR T cell not only blocks apoptosis triggered by FasL, but results in co-stimulation, which promotes CAR T cell survival and proliferation.
  • These data support the potential of this Fas-CD40 chimera to render T cell therapies resistant to FasL-mediated cell death and improve their effectiveness against solid tumors.

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023
AACR, Biotechnology, Fusome, CD19, IL-7, Cell, Hematological Cancer Research Investment and Education Act, CAR, HIP, Animal, Patient, Immune system, Poster, Neoplasm, SANA, Sana, Therapy, IND, Vaccine, Pharmaceutical industry

“At AACR, we presented data highlighting the potential of our hypoimmune platform to “hide” allogeneic CAR T cells from immune recognition, improving CAR T cell persistence and anti-tumor effect.

Key Points: 
  • “At AACR, we presented data highlighting the potential of our hypoimmune platform to “hide” allogeneic CAR T cells from immune recognition, improving CAR T cell persistence and anti-tumor effect.
  • Other data highlighted the progress and potential of SG299, the first drug candidate from our fusogen platform, in generating CD19-directed CAR T cells with in vivo delivery.
  • The study results showed that HIP CD19-directed CAR T cells were functionally immune evasive in allogeneic humanized mouse models.
  • When given systemically, IL-7 supported the expansion of in vivo fusosome-generated CAR T cells and increased anti-tumor efficacy compared to fusosome only.